Latest advances in predicting DILI in human subjects: focus on biomarkers

Bibliography

• Przybylak KR, Cronin MT. In silico models for drug-induced liver injury - current status. Expert Opinion: Drug Metab Toxicol 2012;8:201-17
   PubMed Web of Science ®Google Scholar
• Amacher D. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Apply Pharmacol 2010;245:134-42
   PubMed Web of Science ®Google Scholar
• Cheng F, Theodorescu D, Shulman I, Lee J. In vitro transcriptomic prediction of hepatotoxicity for early drug discovery. J Theor Biol 2011;290:27-36
   PubMed Web of Science ®Google Scholar
• Bauman J, Kelly J, Tripathy S, Can in vitro metabolism-dependent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem Res Toxicol 2009;2:332-40
   Google Scholar
• Mandenius C, Andersson T, Alves P, Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report of the Vitrocellomics EU-project. Altern Lan Anim 2011;2:147-71
   Google Scholar
• Liu Z, Shi Q, Ding D, Translating clinical findings into knowledge in drug safety evaluation—drug induced liver injury prediction systems (DILIps). PLoS Comput Biol 2011;7:e1002310
   PubMed Web of Science ®Google Scholar
• Shi Q, Hong H, Senoir J, Tong W. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2010;4:225-34
   PubMed Web of Science ®Google Scholar
• Zhang M, Chen M, Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced injury in humans. Chem Res Toxicol 2012;25:122-9
   PubMed Web of Science ®Google Scholar
• Liss G, Rattan S, Lewis J. Predicting and preventing acute drug-induced liver injury: what's new in 2010. Expert Opinion: Drug Metab Toxicol 2010;9:1-15
   Google Scholar
• Graham D, Drinkard C, Shatin D, Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001;286:831-3
   PubMed Web of Science ®Google Scholar
• Guidance for Industry. Drug-Induced Liver Injury: Pre-marketing Clinical Evaluation. July 2009. U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research. Accessed from http://www.fda.gov/Drugs/GuidanceComlianceRegulatoryInformation/guidances/default.htm [Last accessed 25 June 2012]
   Google Scholar
• Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. 2nd edition. Lippincott Williams & Wilkins; Philadelphia: 1999
   Google Scholar
• Singla R, Sharma S, Mohan A, Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010;132:81-6
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-90
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Dierkhising R, Kremers W, Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010;105:2396-404
   PubMed Web of Science ®Google Scholar
• Andrade R, Lucena MI, Fernandez C, Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-21
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonjovsky HL, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the united States. Gastroenterology 2008;135:1924-34
   PubMed Web of Science ®Google Scholar
• Lucena M, Andrade R, Kaplowitz N, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49:2001-9
   PubMed Web of Science ®Google Scholar
• Reuben A, Koch DG, Lee WM, Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-9
   PubMed Web of Science ®Google Scholar
• Stepan A, Walker D, Bauman J, Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the Unites States. Chem Res Toxicol 2011;24:1345-410
   PubMed Web of Science ®Google Scholar
• Laverty H, Antoine D, Benson C, The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol 2010;66:961-76
   PubMed Web of Science ®Google Scholar
• Cosgrove B, Alexopoulos L, Hang T, Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol Biosyst 2010;6:1195-206
   PubMed Web of Science ®Google Scholar
• Daly AK, Donaldson PT, Bhatnagar P, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816-19
   PubMed Web of Science ®Google Scholar
• Daly AK. Drug-induced liver injury: past, present, and future. Pharmacogenomics 2010;5:607-11
   Google Scholar
• Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009;29:400-11
   PubMed Web of Science ®Google Scholar
• Watkins PB. Biomarkers for the diagnosis and management of drug-induced liver injury. Semin Liver Dis 2009;4:393-9
   Google Scholar
• Russman S, Jetter A, Kullak-Ublick G. Pharmacogenetics of drug-induced liver injury. Hepatology 2010;52:748-861
   PubMed Web of Science ®Google Scholar
• Lucena M, Molokhia M, Shen Y, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011;141:338-47
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Daly AK, Henderson J, Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010;53:1049-53
   PubMed Web of Science ®Google Scholar
• Daly AK. Using the genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol 2012;52:21-35
   PubMed Web of Science ®Google Scholar
• Spraggs C, Parham L, Hunt C, Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes. Clin Pharm Ther 2012;91:647-52
   PubMed Web of Science ®Google Scholar
• Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010;196:407-18
   PubMedGoogle Scholar
• Mallal S, Phillips E, Carosi G, HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79
   PubMed Web of Science ®Google Scholar
• Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009;13:1-9
   PubMed Web of Science ®Google Scholar
• Phillips E, Mallal S. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010;11:973-87
   PubMed Web of Science ®Google Scholar
• Berka N, Gill J, Liacini A, Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus - positive patients from southern Alberta. Hum Immunol 2012;73:164-7
   PubMed Web of Science ®Google Scholar
• Overview: abacavir. Accessed from http://livertox.nlm.nih.gov/abacavir.htm [Last accessed 7 August 2012]
   Google Scholar
• Martin M, Klein T, Dong B, Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012;91:734-8
   PubMed Web of Science ®Google Scholar
• Soni S, Churchill D, and Gilleece Y. Abacavir-induced hepatotoxocity: a report of two cases. AIDS 2008;30:2557-8
   Google Scholar
• Teixera R, Morato R, Cabello P, Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011;106:716-24
   PubMed Web of Science ®Google Scholar
• Chang J, Liu E, Lee C, UGTA1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications. Int J tuberc Lung Dis 2012;16:376-8
   PubMed Web of Science ®Google Scholar
• An H, Wu X, Wang Z, NAT 2 and CYPE1 polymorphisms associated with antituberculosis drug-induce hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 2012;39:535-43
   PubMed Web of Science ®Google Scholar
• Tang S, Lv X, Zhang Y, CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study. J Clin Pharm Ther 2012. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ben Mahmoud L, Ghozzi H, Kamoun A, Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathol Bio (Paris) 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• An H, Wu X, Wang Z, The associations of polymorphism of N-acetyltransferase 2 gene is associated with antituberculosis drug-induced hepatotoxicity in tuberculosis patients. Zhonghua Yu Fang Yi Xue Za Zhi 2011;45:36-40
   PubMedGoogle Scholar
• Nanashima K, Mawatari T, Tahara N, Genetic variants in antioxidant pathway: risk factors for hepatoxicity for tuberculosis patients. Tuberculosis (Edinb) 2012;92:253-9
   PubMed Web of Science ®Google Scholar
• Park W, Kim W, Lee K, Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J of Infect 2010;61:323-9
   PubMed Web of Science ®Google Scholar
• Winnike J, Wright F, Macdonald J, Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 2010;88:45-51
   PubMed Web of Science ®Google Scholar
• Buchard A, Eefsen M, Semb S, The role of the glutathione S-transferase genes GSTT1, GSTM1, and GSTP1 in acetaminophen-poisoned patients. Clin Toxicol 2012;50:27-33
   Web of Science ®Google Scholar
• Zimmerman H, Maddrey W. Acetominophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995;22:767-73
   PubMed Web of Science ®Google Scholar
• Khalid S, Lane J, Navarro V, Garcia-Tsao G. Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol 2009;7:994-9
   PubMed Web of Science ®Google Scholar
• Rumack B. and Bateman D. Acetominophen and acetylcysteine dose and duration: past, present, and future. Clin Toxicol 2012;50:91-8
   PubMed Web of Science ®Google Scholar
• Waters N. The role of metabonomics at the interface between drug metabolism and safety assessment. Curr Drug Metab 2010;11:686-92
   PubMed Web of Science ®Google Scholar
• O’Connell T, Watkins P. The application of metabonomics to predict drug-induced liver injury. Clin Pharmacol Ther 2010;88:394-9
   PubMed Web of Science ®Google Scholar
• Leung L, Kalgutkar A, and Obach R. Metabolic activation in drug-induced liver injury. Drug Metab Rec 2012;44:18-33
   PubMed Web of Science ®Google Scholar
• Amacher DE. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opinion: Drug Metab Toxicol 2012;8:335-47
   PubMed Web of Science ®Google Scholar
• McBurney RN, Hines WM, Vontungeln LS, The liver toxicity biomarker study phase I. Markers for the effects of tolcapone or entecapone. Toxicol Pathol 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Huang J, Shi W, Zhang J, Genomic indicators in the blood predict drug-induced liver injury. Pharmacogenomics J 2010;10:267-77
   PubMed Web of Science ®Google Scholar
• McBurney RN, Hines W, Von Tungelin LS, The liver toxicity biomarker study: phase design and preliminary results. Toxicology Pathol 2009;37:52-64
   PubMed Web of Science ®Google Scholar
• Xu J, Dunn M, Smith A, Assessment of hepatotoxicity potential of drug candidate molecules including kinase inhibitors by hepatocyte imaging assay technology and bile flux imaging assay technology. Methods mol Biol 2012;795:83-107
   PubMedGoogle Scholar
• Van Summeren A, Renes J, van Delft J, Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicol In Vitro 2012;26:373-85
   PubMed Web of Science ®Google Scholar
• Kostenko L, Kjer-Neilsen L, Nicholson I, Rapid screening for the detection for HLA-B57 and HLA B58 in prevention of drug hypersensitivity. Tissue Antigens 2011;78:11-20
   PubMed Web of Science ®Google Scholar
• Kauf TL, Farkouh RA, Earnshaw SR, Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 2010;28:1025-39
   PubMed Web of Science ®Google Scholar
• Charneira C, Godinho A, Conceicao Oliveria M, Reactive aldehyde metabolites from the anti-HIV drug Abacavir: amino acid adducts as possible factors in Abacavir toxicities. Chem Res Toxicol 2011;24:2129-41
   PubMed Web of Science ®Google Scholar
• Ostrov DA, Grant BJ, Pompeu YA, Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012; [epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Krawczyk M, Mullenbach R, Weber S, Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 2010;7:669-80
   PubMed Web of Science ®Google Scholar
• Bell L, Theodorakis J, Vuppalanchi R, Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010;51:111-20
   PubMed Web of Science ®Google Scholar
• Bell L, Vuppalanchi R, Watkins P, Serum proteomic profiling in patients with drug-induced liver injury. Alimentary Pharmacology and Therapeutics 2012;35:600-12
   PubMed Web of Science ®Google Scholar
• Ferre N, Martinez-Clemente M, Lopez-Parra M, Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol 2009;296:G553-62
   PubMed Web of Science ®Google Scholar
• Van Summeren A, Renes J, Bouwman FG, Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci 2011;120:109-22
   PubMed Web of Science ®Google Scholar
• Jaeschke H, McGill M, Ramachandran A. Letter to the Editor: pathophysiology relevance of proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci 2011;121:428-30
   PubMed Web of Science ®Google Scholar
• Luo Y, Rana P, and Will Y. Palmitate increases the susceptibility of cells to drug-induced toxicity : an invitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci 2012. [Epub ahead of print]
   Web of Science ®Google Scholar
• Clayton T, Lindon J, Cloarec O, Pharmaco-metabonomics phenotyping and personalized drug treatment. Nature 2006;440:1073-7
   PubMed Web of Science ®Google Scholar
• Lee S-W, Chung L S-C, Huang H-H, NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010;14:622-6
   PubMed Web of Science ®Google Scholar
• Kim S, Kim S, Yoon H, TNF-alpha genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. Liver International 2011;1-6
   Google Scholar
• Yimer G, Ueda N, Habtewold A, Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011;6:1-8
   Google Scholar
• Henderson C, Wolf C, Kitteringham N, Increased resistance to acetaminophen toxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci 2000;23:12741-5
   Google Scholar
• Usui T, Hashizume T, Katsumata T, In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. Drug Metab Dispos 2011;39:1303-10
   PubMed Web of Science ®Google Scholar
• Starkey Lewis PJ, Dear J, Platt V, Circulative microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011;54:1767-76
   PubMed Web of Science ®Google Scholar
• Adebayo D, Mookerjee RP, Jalan R. Mechanistic biomarkers in acute liver injury: are we there yet? J Hepatol 2012;56:1003-5
   PubMed Web of Science ®Google Scholar
• Lewis JH. The adaptive response (drug tolerance) helps prevent drug-induced liver disease. Gastroenterology & Hepatology 2012;8:5-333-6
   Google Scholar
• Lee MH, Stocker SL, Anderson J, Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? Intern Med J 2012;42:411-16
   PubMed Web of Science ®Google Scholar
• Xu C, Reck B, Xue Z, Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010;102:1371-7
   PubMed Web of Science ®Google Scholar
• Singer JB, Lewitzky S, Leroy E, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42:711-14
   PubMed Web of Science ®Google Scholar